Biological
nanoparticles, such as exosomes, offer an approach to
drug delivery because of their innate ability to transport biomolecules.
Exosomes are derived from cells and an integral component of cellular
communication. However, the cellular cargo of human exosomes could
negatively impact their use as a safe drug carrier. Additionally,
exosomes have the intrinsic yet enigmatic, targeting characteristics
of complex cellular communication. Hence, harnessing the natural transport
abilities of exosomes for drug delivery requires predictably targeting
these biological nanoparticles. This manuscript describes the use
of two chemical modifications, incorporating a neuropilin receptor
agonist peptide (iRGD) and a hypoxia-responsive lipid for targeting
and release of an encapsulated drug from bovine milk exosomes to triple-negative
breast cancer cells. Triple-negative breast cancer is a very aggressive
and deadly form of malignancy with limited treatment options. Incorporation
of both the iRGD peptide and hypoxia-responsive lipid into the lipid
bilayer of bovine milk exosomes and encapsulation of the anticancer
drug, doxorubicin, created the peptide targeted, hypoxia-responsive
bovine milk exosomes, iDHRX. Initial studies confirmed the presence
of iRGD peptide and the exosomes’ ability to target the αvβ3 integrin, overexpressed on triple-negative
breast cancer cells’ surface. These modified exosomes were
stable under normoxic conditions but fragmented in the reducing microenvironment
created by 10 mM glutathione. In vitro cellular internalization studies
in monolayer and three-dimensional (3D) spheroids of triple-negative
breast cancer cells confirmed the cell-killing ability of iDHRX. Cell
viability of 50% was reached at 10 μM iDHRX in the 3D spheroid
models using four different triple-negative breast cancer cell lines.
Overall, the tumor penetrating, hypoxia-responsive exosomes encapsulating
doxorubicin would be effective in reducing triple-negative breast
cancer cells’ survival.